-
The FDA has approved a new combination product for the treatment of type 2 diabetes mellitus. Sitagliptin, the recently approved dipeptidyl peptidase-4 (DPP-4) inhibitor is combined with metformin in two different dose configurations. Sitagliptin/metformin is marketed by Merck & Co., Inc as Janumet.
-
A simple questionnaire can identify individuals at risk for chronic kidney disease.
-
A new class of drug has been approved for the treatment of cutaneous T-cell lymphoma (CTCL) such as mycosis fungoides.
-
Persons who do not suffer hyperhidrosis (HID) may be surprised to learn that it has been associated with both occupational and physical impairment, as well as limitations in social interaction.
-
Torcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, has been in development by Pfizer for nearly 15 years.
-
For women, up to 20% of all coronary events occur in the absence of traditional major risk factors, and many women with these risk factors do not develop coronary events.
-
Patients at high risk for VTE should be treated with three times daily UH, while patients at lower risk may be treated with twice daily therapy.
-
The ECG Figure in the article was obtained from an older woman who was seen in the Emergency Department with a chief complaint of weakness of several days duration.
-
In a group of smokers who were hospitalized with cardiac symptoms, a combination of 12 weeks of behavior modification counseling plus pharmacotherapy resulted in higher tobacco abstinence rates, lower re-hospitalization rates, and markedly reduced mortality rates compared with usual care over two years of follow-up.
-
When compared to The Zone, Ornish, or LEARN diets, the very low carbohydrate diet (Atkins), showed that premenopausal, overweight, and obese women lost more weight and had the most beneficial metabolic effects at 12 months.
